Smith & Nephew plc (Smith Nephew) develops, manufactures, markets and sells medical devices and services.
The company works to improve the quality of healthcare through its investment in new technologies and services, industry-leading medical education and clinical evidence programmes, and efficient and resilient manufacturing and distribution.
The company takes its innovation to market through three global business units: Orthopaedics, Sports Medicine & Ear, Nose and Throat (ENT), and Advance...
Smith & Nephew plc (Smith Nephew) develops, manufactures, markets and sells medical devices and services.
The company works to improve the quality of healthcare through its investment in new technologies and services, industry-leading medical education and clinical evidence programmes, and efficient and resilient manufacturing and distribution.
The company takes its innovation to market through three global business units: Orthopaedics, Sports Medicine & Ear, Nose and Throat (ENT), and Advanced Wound Management (AWM). These business units are responsible for strategy and global marketing, and contain specialist sales and support teams dedicated to serving the specific requirements of its healthcare professional customers.
Orthopaedics
Orthopaedics includes an innovative range of hip, knee, and shoulder replacement systems, robotics-assisted and digital enabling solutions that empower surgeons, and Trauma & Extremities products used to stabilise severe fractures and correct hard tissue deformities.
Sports Medicine & ENT
The company’s Sports Medicine & ENT business unit offers advanced products and instruments used to repair or remove soft tissue. It serves growing markets where unmet clinical needs provide opportunities for procedural and technological innovation.
Advanced Wound Management
The company’s Advanced Wound Management business unit provides a comprehensive set of products and services to meet broad and complex clinical needs across hard-to-heal wounds, delivering on its mission to shape what is possible in wound care.
Strategy
The company’s strategies are to transform through innovation and acquisition; accelerate profitable growth through prioritisation and customer focus; and strengthen the foundation to serve customers sustainably and simply.
New Products in 2024
In 2024, the company continued to expand its portfolio with major new platforms and product enhancements that address unmet clinical needs and support its higher-growth ambitions.
Orthopaedics
In Orthopaedics, new products included implant systems for hips and shoulders, and building out the capabilities of the company’s CORI Surgical System.
The company announced a major new hip system, the CATALYSTEM Primary Hip System. CATALYSTEM is designed to address the evolving demands of primary hip surgery, including the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs).
The company introduced a new OXINIUM option for its LEGION Hinged Total Knee (HK) System, making this proprietary material, with its leading wear and corrosion resistance technology, available to hinged knee patients for the first time.
The company moved to full commercial launch of the AETOS Shoulder System in the US, and announced 510(k) clearance for its use with ATLASPLAN 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. AETOS will enable the company to compete effectively in total shoulder arthroplasty, one of the fastest-growing segments in Orthopaedics, with an estimated 250,000 procedures in the US by 2025.
The company also introduced TOTAL ANKLE Patient-Matched Guides to help surgeons plan and perform total ankle replacement procedures. Total ankle replacements are historically uncommon, but this is a high-growth market bolstered by the rising prevalence of osteoarthritis in adults, and influenced by growing patient preference for joint preservation and restoration.
For the CORI Surgical System, the company announced new CORIOGRAPH Pre-Operative Planning and Modelling Services, making CORI the only orthopaedic robotics-assisted system to offer either intra-operative image-free or image-based registration for knee implants, enabling the surgeon to choose whether or not to perform a pre-operative MRI scan. This is one of a number of distinct features for CORI, including supporting revision knee procedures and offering both burr and saw cutting options.
Sports Medicine
In Sports Medicine, the company completed the acquisition of CartiHeal, the developer of the CARTIHEAL AGILI-C Cartilage Repair Implant, a novel Sports Medicine technology for cartilage regeneration in the knee. The company has made good progress on market development activities in the first year of ownership, including clinical strategy and reimbursement milestones.
The company continued to invest behind Arthroscopic Enabling Technology. During the second quarter, the company introduced the INTELLIO SHIFT System, which combines the company’s leading COBLATION and DYONICS resection technologies into a single controller alongside a multifunctional foot pedal, simplifying the operating room experience for surgeons. The company also launched an updated INTELLIO cart, updated software for the INTELLIO Tablet, which serves as both a control device and image storage for the INTELLIO Tower, and introduced the EVO 4K Image Management System.
In ENT, the company launched the ARIS COBLATION Turbinate Reduction Wand. This utilises the company’s advanced COBLATION Plasma Technology to provide a minimally invasive way to reduce hypertrophic turbinates, a condition that requires 350,000 procedures per annum in the US.
Advanced Wound Management
In Advanced Wound Management, the company launched the RENASYS EDGE NPWT System, designed to reduce inefficiency and complexity, and features an improved user interface for enhanced intuitiveness and simplicity, and a durable pump built to offer virtually maintenance-free use. The launch commenced in the U.S. and expanded into Europe in the second half of 2024.
The company also continued its high cadence of incremental innovation in skin substitutes, with the launch of GRAFIX PLUS in the second quarter, an easier-to-handle new version in its lead product family, targeting the growing post-acute market.
Clinical, scientific, and real-world evidence continues to play a critical role in the company’s go-to-market strategy, with compelling and differentiating data supporting key brands in 2024. This included the first randomised controlled trial with the REGENETEN Bioinductive Implant, market-leading 20-year survivorship data for OXINIUM Technology with highly cross-linked polyethylene among all total hip replacement bearing combinations, and early impressive results for the OR30 Dual Mobility Hip, LEGION CONCELOC Cementless Knee, and revision total knee arthroplasty using the CORI Surgical System. In Advanced Wound Management, the company also published new data supporting the use of PICO SNPWT to reduce surgical site infections and using ALLEVYN LIFE Dressing in a pressure injury prevention protocol.
The company’s CORI Surgical System incorporates Personalised Planning powered by AI, and RIINSIGHTS Data Visualization Platform, two solutions that transform data into contextual intelligence by enabling surgeons to see how pre-operative surgical plans and intra-operative decision making link to post-operative outcomes.
Orthopaedics
The company’s Orthopaedics business unit offers a leading portfolio of hip and knee implants, robotics, and digital enabling technologies driving procedural innovation, and a strengthened Trauma & Extremities portfolio.
The company’s innovative implants are designed to mimic natural movement and are manufactured using materials with a track record of longevity and performance. The addition of the company’s CORI Surgical System robotics platform delivers accuracy, performance, and efficiency to the surgical procedure. The company is well positioned as the supplier of choice for surgeons across the globe.
Orthopaedics includes an innovative range of hip, knee, and shoulder implants used to replace diseased, damaged, or worn joints, robotics-assisted enabling technologies that improve accuracy and facilitate precision during the surgical procedure, and trauma products used to stabilise fractures and correct bone deformities.
In Orthopaedic Joint Reconstruction, which includes the company’s Hip and Knee Implants and Other Reconstruction segments, the company has a broad, clinically proven, and differentiated portfolio that allows it to compete effectively across a market. This portfolio includes the company’s proprietary OXINIUM Technology and its CORI Surgical System, which is strongly positioned to take advantage of the trends towards robotics-assisted surgery and outpatient joint replacement seen across the segment. The simplicity and efficiency of the company’s complete EVOS Plating System gives it an advantage in the largest segment in Trauma, and its TRIGEN INTERTAN Intertrochanteric Nail is backed by the clinical and economic data to position it as the standard of care for hip fractures, the second-largest segment. In Extremities, the company launched its next-generation shoulder implant, the AETOS Shoulder System, in 2024.
Strategy
The company’s Orthopaedics business unit has an innovative portfolio that allows it to compete in joint reconstruction, robotics-enabled procedures, and Trauma & Extremities markets. The company’s areas of focus include advancing innovative surgical solutions and optimising the use of working capital.
The company’s initiatives are designed to drive growth across the Orthopaedic business unit. In joint reconstruction and robotics, the company aims to accelerate growth by focusing on robotically enabled knee and hip procedures using the CORI Surgical System. Additionally, the company will continue to leverage the unique material properties of its OXINIUM Technology across the knee and hip platform.
For Trauma & Extremities, the company expects to globally scale the EVOS Plating System portfolio to compete more broadly in Trauma centres. Following the launch of its AETOS Total Shoulder System, the company expects to expand its footprint in the shoulder replacement market.
Competition
In the company’s Orthopaedics business unit, it is one of four leading players, competing against US-based companies Stryker, Zimmer Biomet, and DePuy Synthes.
Key products by segment Reconstruction & Robotics Knee Implants
In Knee Implants, the company’s specialised systems include leading products for total primary replacement and revision, as well as partial and patellofemoral joint resurfacing procedures, offering surgeons and patients the benefits of many proprietary technologies.
These include a unique kinematic knee, the JOURNEY II Total Knee Arthroplasty System, which features OXINIUM Technology and has been shown to replicate normal knee shape, position, and motion. The company’s LEGION CONCELOC Cementless Total Knee System uses innovative 3D-printed cementless technology to achieve biological fixation, bringing efficiency and versatility to the operating room (OR).
Hip Implants
The Hip Implants portfolio is headlined by the POLAR3 Total Hip Solution, which has among the lowest revision rates in total hip arthroplasty. The company’s OR30 Dual Mobility System is the first system to use the latest OXINIUM DH Advanced Bearing Technology. Dual mobility hip implants are used in primary, as well as revision procedures. In addition, the company offers a full breadth of stems to address surgical needs, including the ANTHOLOGY Hip System. For revisions, the REDAPT Revision Hip System features CONCELOC Technology.
Further strengthening the company’s Hip Implant portfolio, the company launched the CATALYSTEM Primary Hip System in 2024. Building on the clinical success of its POLARSTEM Hip System, the CATALYSTEM System is designed to address the changing demands of primary hip surgery. The CATALYSTEM Primary Hip System optimises performance with patent-pending ACCUBROACH Technology for reproducible implant seating in just one modular tray. It is the only cementless stem of its kind to feature OXINIUM Technology bearing material.
Other Reconstruction
The company’s Other Reconstruction business includes the CORI Surgical System, one of the most advanced and efficient handheld robotics solutions. CORI is a smaller, portable solution capable of performing robotics-assisted knee and computer-guided hip surgery on a single platform. In robotics-assisted knee procedures, CORI utilises handheld precision milling, which allows surgeons to execute Total Knee Arthroplasty and Unicondylar Knee Arthroplasty procedures with reproducible accuracy. The proprietary smart mapping feature creates a 3D image of the patient's anatomy in surgery, eliminating the time, costs, and radiation exposure associated with pre-operative CT scans.
In 2024, the company launched the CORIOGRAPH pre-operative planning and modelling service that delivers the unique surgical planning solution desired by some surgeons. The addition of pre-operative planning makes the CORI Surgical System even more versatile and flexible than before. The proprietary software of CORI 3.0 allows CORI to utilise its proven image-free surface mapping and image-based planning solutions for the right indications.
RLHIP NAVIGATION further expands indications on the CORI Surgical System. When combined with the company’s Hip Implants, such as the CATALYSTEM Primary Hip System, POLAR3 Total Hip Solution, and OR30 Dual Mobility System, as well as complementary tools to assess spinopelvic mobility (RLHIP MODELER), RLHIP on CORI delivers a comprehensive solution for navigated total hip arthroplasty. RI.HIP NAVIGATION and RI.HIP MODELER are designed to help maximise accuracy and reproducibility by delivering patient-specific component alignment.
The CORI Surgical System is currently the only solution indicated for robotics-enabled knee procedures across the full continuum of care—partial, total, and revision knee arthroplasty.
In addition, Personalised Planning guided by RIINSIGHTS enables surgeons to set the initial implant placement within the total knee arthroplasty procedure based on AI-guided reference values and the surgeon's planning preferences for specific implants and patient-specific deformities.
The company’s portfolio includes differentiated technology across the major categories of Plates and Screws, Intramedullary Nails, Hip Fracture Limb Restoration, Extremities, and Shoulder Replacement.
Leading products include the EVOS Plating System, which includes a wide range of clinical indications from mini and small to large fragment and periprosthetic. Designed to offer surgeons an all-inclusive, expansive plating portfolio, EVOS provides the simplicity of logically organised instrumentation with advanced implant solutions that meet the demands and expectations of Trauma surgeons. In 2025, the company will further expand its EVOS offering, with the introduction of EVOS Pelvic and EVOS Patella.
The portfolio also includes the TRIGEN INTERTAN Hip Fracture System, which is backed by many years of strong clinical evidence, and SMART TSF, which increases the capabilities of the TAYLOR SPATIAL FRAME External Fixator. In 2025, the company will expand its TRIGEN portfolio with the introduction of the TRIGEN MAX Tibial Nailing System.
In the company’s Upper Extremities portfolio, the AETOS Shoulder System, indicated for both anatomic and reverse total shoulder arthroplasty, is designed to restore patients' range of motion and help minimise arthritic shoulder pain. It complements the company’s market-leading sports medicine shoulder repair and biologics solutions.
In the company’s Lower Extremities portfolio, the company expanded its offering with the launch of TOTAL ANKLE Patient-Matched Guides in 2024. TOTAL ANKLE Patient-Matched Guides help surgeons visualise outcomes through pre-operative planning and accurate, efficient instrumentation. The company also launched the LEOS Plating System and LEOS Cannulated Screw System in 2024. These systems feature titanium fixation technology, simplified instrumentation, and modularity designed to offer surgeons peace of mind across key foot procedures in day-to-day practice.
Sports Medicine & ENT
The company’s Sports Medicine & ENT business unit leads with innovative procedural solutions to elevate the standard of care in Sports Medicine & ENT. With a comprehensive offering and differentiated technologies backed by clinical evidence, the company helps healthcare professionals get their patients back to a Life Unlimited.
Sports Medicine & ENT operates in growing markets where unmet clinical needs provide opportunities for procedural and technological innovation.
The company has a rich history of product development, and its technologies, instruments, and implants enable surgeons to perform minimally invasive surgery, treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints.
ENT is also an attractive and growing market segment, offering the opportunity to address unmet needs with differentiated procedural solutions. The positive momentum is driven by emerging therapies, changes in the point of care mainly to the office setting, and increasing global access for ENT procedures.
The company offers a portfolio of technologies focused on the unmet needs of some of the most common procedures general and paediatric ENT surgeons perform today. These include tonsillectomies, epistaxis (severe nosebleeds), and tympanostomies (insertion of ear tubes).
Strategy
The company’s business unit is driven by three strategic priorities: innovation, market development, and commercial execution.
The company’s Sports Medicine & ENT business is founded on procedural innovation, with differentiated technologies that shape clinical outcomes across the globe. The company’s portfolio continues to demonstrate strong growth across key segments, and it has an innovative pipeline in development.
The company is committed to investments in key areas, such as clinical evidence, medical education, and surgeon training for continued market development around key procedures. The company’s commercial initiatives reflect balanced selling across segments and regions, aligned priorities, and a customer-centric, winning mentality.
Competition
In Sports Medicine, the company holds a leading position behind Arthrex and also competes against Stryker and DePuy Mitek.
Key products by segment Sports Medicine Joint Repair
The company’s Sports Medicine Joint Repair business offers innovative procedural solutions for repairing soft tissue injuries, including systems of specialised implants and instruments to facilitate arthroscopic procedures across sports medicine for knees, shoulders, hips, and small joints. For shoulder repair, the company develops products for rotator cuff repair (RCR) and instability repair to help address pain and restore function.
Advanced Healing Solutions for RCR include the innovative REGENETEN Implant. With at least 14 published clinical studies, including more than 700 patients, the REGENETEN Implant has been shown to change the course of tear progression in studies, aid return to normal activity, and reduce re-tears versus conventional surgery. The HEALICOIL platform of shoulder anchors features an open architecture designed to facilitate healing and is available in its REGENESORB material, which can be shown to be absorbed and replaced by bone within 24 months.
In 2024, the company expanded its HEALICOIL platform with the introduction of HEALICOIL with MINITAPE Suture Anchor. MINITAPE Suture Tape has a low profile and coreless design, which has been shown to provide a lower and more evenly distributed level of pressure.
The company further strengthened its shoulder portfolio by building on its Q-FIX Suture Anchor offering with the introduction of the Q-FIX KNOTLESS Suture Anchor and the Q-FIX with MINITAPE Suture Anchor. Designed for procedures, such as RCR, where anatomic space is limited, the Q-FIX All-Suture Anchor provides the benefits of a small, soft anchor with the fixation characteristics of traditional anchor designs. This radially expanding anchor offers compact size, high fixation strength, low displacement, and consistent deployment. Additionally, the Q-FIX KNOTLESS All-Suture Anchor is designed for controlled tensioning post-deployment. Its suture lock feature allows for best-in-class soft tissue security, and it offers streamlined suture shuttling.
In knee repair, arthroscopic repair techniques have become more prevalent and widely recognised for the treatment of meniscal tears in recent years. The company’s All Tears, All Repairs Meniscal Repair portfolio provides surgeons with unsurpassed options and possibilities for meniscal repair. In 2024, the company celebrated 30 years of saving the meniscus and advancing the standard of care towards meniscal repair.
The CARTIHEAL AGILI-C Cartilage Repair Implant is a novel Sports Medicine technology for cartilage regeneration in the knee. CARTIHEAL AGILI-C is a porous, biocompatible, and resorbable scaffold, which repairs regeneration of the articular cartilage and restoration of its underlying subchondral bone.
The company also offers a comprehensive ligament portfolio of high-quality products and thoughtful techniques to address the full spectrum of ligament pathologies and concomitant injuries. Building upon the company’s trusted legacy of data-driven solutions, it continues to innovate in this space, and in 2024, the company launched new indications for the REGENTEN Bioinductive Implant.
The company’s hip preservation portfolio contains a comprehensive offering of technologies and techniques, establishing the company as a leader and innovator in the hip repair segment. The CAP-FIX Capsular Management Family addresses all capsular management needs, from open to close. The company is committed to redefining healing potential in gluteus medius repairs, with the use of the REGENETEN Implant. In line with the company’s shoulder repair offering, the company also launched the Q-FIX KNOTLESS Suture Anchor for hip repair.
In 2024, the company launched new procedure solutions in foot and ankle soft tissue repair with the introduction of ULTRABRACE and ULTRABRIDGE Procedural Kits for ankle instability and Achilles reconstruction, respectively. As a core technology in the company’s ULTRABRACE Adjustable Ankle Instability Technique, and a step forward in ankle instability repair, the company introduced Q-FIX with Needles in 2024. Q-FIX with Needles features integrated needles for open procedures, which combine with the system's deployment consistency and strength. The company’s core platform technology is designed specifically for the foot and ankle surgeon and provides a significant opportunity for growth.
In addition, with the REGENETEN Implant, the company offers an innovative biologic solution that can be used to augment insertional or midsubstance Achilles repair.
Arthroscopic Enabling Technologies
In Arthroscopic Enabling Technologies, the company’s products facilitate arthroscopic surgical procedures, providing a strong foundation of platforms and associated consumables required to perform arthroscopic surgery, including visualisation, fluid management, COBLATION, and mechanical resection. The INTELLIO Connected Tower Solution unites high-definition imaging solutions, energy-based and mechanical resection platforms, fluid management, and access technologies. The company launched the INTELLIO Tablet in 2024, a durable medical-grade tablet incorporating its proprietary software for use in conjunction with the INTELLIO Connected Tower. From one centralised location, operating room staff have the ability to remotely control and adjust the INTELLIO 4K Surgical Imaging System, the DYONICS POWER II Control System, the WEREWOLF COBLATION System, and the DOUBLEFLO Inflow/Outflow Pump.
The LENS 4K Surgical Imaging System uses 4K ultra high definition (UHD) image quality and network connectivity in a three-in-one console for multi-speciality environments.
The company’s WEREWOLF Controller enables surgeons to remove soft tissue precisely in a variety of arthroscopic procedures. With COBLATION use in chondroplasty of the knee, patients experienced significantly less bleeding post-operatively.
In mechanical resection, the company launched the PLATINUM Handpiece in 2024. Building on the performance of the company’s existing technology, the PLATINUM Handpiece is designed ergonomically with surgeon comfort in mind, accommodating a range of grip styles. Facilitating the removal of dense bone and tissue in large joints, it features improved torque between the working range of 4,000-10,000 RPM, when compared to the DYONICS POWERMAX ELITE Shaver System.
Ear, Nose and Throat (ENT)
In ENT, the company’s COBLATION Plasma Technology, which has been used to remove tonsils and adenoids for over 20 years, has an ability to remove tissue at low temperatures with minimal damage to surrounding tissue.
Evidence shows that COBLATION Intracapsular Tonsillectomy (CIT) procedures offer less pain, quicker recovery, and a decreased risk of post-operative bleeding with similar outcomes to total tonsillectomies. The company offers a full portfolio of COBLATION Wands for CIT procedures.
The ARIS COBLATION Turbinate Reduction Wand utilises the company’s advanced COBLATION Plasma Technology to provide a minimally invasive way to reduce hypertrophic turbinates. It provides targeted hemostasis with built-in bipolar coagulation function.
The company’s Tula System provides an in-office alternative to traditional tympanostomy using a local anaesthesia system and an automated, one-click tube delivery device.
As part of the company’s comprehensive portfolio of epistaxis (nosebleed) solutions, RAPID RHINO Epistaxis Products are inflatable tamponades, which are easy to insert and remove, with an ultra-low profile and self-lubricating hydrocolloid fabric. In addition, the company markets a range of dissolvable and removable post-operative nasal dressings.
Advanced Wound Management
Through the company’s extensive portfolio, designed to meet broad and complex clinical needs, the company helps healthcare professionals solve the challenges of preventing and healing wounds.
Long-term growth continues to be driven by the needs of an ageing population and an increasing prevalence of obesity, diabetes, and vascular disease. These conditions are key drivers of wound prevalence and contribute to the pressure on healthcare spending. Healthcare systems need to do more with less, such as enabling patients to be treated faster, with fewer resources, or moving them from acute to homecare settings. The prevention of wounds is also an important focus, with healthcare systems increasingly working proactively to avoid wounds, such as pressure injuries and surgical site complications.
In Advanced Wound Management, the company seeks to help healthcare systems through innovation in products and services, to prevent wounds or deliver accelerated healing. The company does this across its three segments of Advanced Wound Care, Advanced Wound Bioactives, and Advanced Wound Devices.
Strategy
The company’s vision of Shaping What's Possible in Wound Care is delivered through product innovation with strong clinical evidence that enables protocol compliance to ensure optimal patient outcomes.
Innovation includes new product development, line extensions, and acquisitions for both clinicians and patients.
To drive ever-improving commercial execution, the company seeks to inspire, engage, and align on its global strategy across all regions and functions as efficiently as possible. Through these strategic priorities, the company is driving performance and supporting the delivery of its global Strategy for Growth to Strengthen, Accelerate, and Transform.
Competition
The company operates in all three categories in wound care and has the second largest business globally in terms of revenue. In the Advanced Wound Care segment, the company competes in dressings with Mölnlycke (Sweden), Coloplast (Denmark), and ConvaTec (UK). In Advanced Wound Bioactives, the company has leadership positions in a number of its respective categories, and it has the only US Food and Drug Administration (FDA) approved enzymatic debrider. In Advanced Wound Devices, the company is the primary challenger to Negative Pressure Wound Therapy incumbent Solventum.
Key products by segment
Advanced Wound Care
The company started as a wound care company, and through its Advanced Wound Care business, it has grown to be a leader in the segment. Today, its portfolio includes products that are designed to manage exudate and infection, protect the skin, and help prevent pressure injuries.
ALLEVYN Wound Dressings are a trusted leader when it comes to providing an optimal environment for healing. The company’s dressings provide the essentials customers expect from a foam dressing, such as proven performance to absorb, protect, and be gentle on the skin, as well as much more.
The 'much more' comes with ALLEVYN's extensive range of shapes and sizes, as well as its unique technologies. ALLEVYN LIFE Foam Dressing, for example, has ExULOCK and ExuMASK technologies.
ExULOCK hyper-absorbent lock-away technology absorbs exudate and spreads it laterally across the dressing to utilise the entire dressing area while locking it in to help prevent leakage and to help control malodour.
ExuMASK change indicator technology minimises the visual impact of absorbed exudate and works as an indicator to know when to change the dressing, which helps minimise clinically unnecessary changes.
The effectiveness of the ALLEVYN Dressing range has been demonstrated across over 138 publications in 19 countries on over 12,000 patients and volunteers.
The company also offers DURAMAX S Silicone Superabsorbent Dressing for highly exuding wounds. Superabsorbers are one of the fastest-growing categories of dressings in Europe.
The company’s infection management range, designed to help reduce the signs and symptoms of infection, includes ACTICOAT Antimicrobial Barrier Dressings, DURAFIBER Ag Absorbent Gelling Silver Fibrous Dressings, ALLEVYN Ag Antimicrobial Foam Dressings, and the company’s range of IODOSORB Cadexomer Iodine products. The company advocates usage to support the principles of antimicrobial stewardship, helping to reduce the spread of antimicrobial resistance and protecting future patients.
The company’s new ALLEVYN Ag SURGICAL antimicrobial foam dressings were recently launched in the US, completing its foam portfolio and supporting growth in expanding market segments.
Advanced Wound Bioactives
The company’s Advanced Wound Bioactives portfolio provides a unique approach to debridement, dermal repair, and tissue substitutes, with considerable evidence supporting their clinical application.
Collagenase SANTYL Ointment (250 units/gram) is the only FDA-approved enzymatic debridement agent indicated for debriding both chronic dermal ulcers and severely burned areas that is available in the US and Canada, with a unique mechanism of action that facilitates removal of necrotic tissue and contributes to the formation of granulation tissue and subsequent epithelialisation of chronic wounds and severely burned areas.
In the company’s skin substitute product range, GRAFIX Placental Membranes and STRAVIX Umbilical Tissues retain the extracellular matrix, growth factors, and native placental components to support wound closure. They are intended for application directly to acute and chronic wounds, and as a surgical cover or barrier. In addition, the company offers OASIS Matrix and OASIS MICRO products, which are naturally derived scaffolds of extracellular matrix, composed of porcine small intestinal submucosa and indicated for the management of a wide range of acute and chronic wounds, burns, and surgical interventions.
Advanced Wound Devices
In Advanced Wound Devices, the company’s portfolio helps improve healing outcomes in chronic wounds, reduce surgical site complications, and facilitate preventative care for pressure injuries. Within the Negative Pressure Wound Therapy (NPWT) category, the company offers single-use and traditional (cannister-based) solutions, offering customers a one-stop shop with great flexibility.
The company’s PICO range of single-use NPWT systems, with its proprietary AIRLOCK Technology layer, has demonstrated significant healing outcomes for chronic wounds and in the reduction of surgical site complications in closed incisions, in a highly portable form that allows patients to continue with their daily activities.
The company’s traditional RENASYS NPWT Systems are easy-to-use platforms with a range of accessories to treat a wide variety of wounds and patients across all care settings. The RENASYS portfolio's newest innovation, RENASYS EDGE, recently won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category. RENASYS EDGE has been designed to be clinically easy to use, and with its self-test functionality, has been shown to deliver higher efficiency and utility.
The VERSA JET Hydrosurgery System uses a saline jet to facilitate precise debridement, helping to streamline and reduce debridement procedures.
Research and Development (R&D)
For the year ended December 31, 2024, the company invested $289 million in R&D.
History
Smith & Nephew plc was founded in 1856. The company was incorporated in 1937.
